{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:08:42Z","timestamp":1785539322495,"version":"3.56.0"},"reference-count":34,"publisher":"BMJ","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine rates of stroke or transient ischaemic attack (TIA) and all cause mortality in patients with a diagnosis of \u201cresolved\u201d atrial fibrillation compared to patients with unresolved atrial fibrillation and without atrial fibrillation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Two retrospective cohort studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>General practices contributing to The Health Improvement Network, 1 January 2000 to 15 May 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Adults aged 18 years or more with no previous stroke or TIA: 11\u2009159 with resolved atrial fibrillation, 15\u2009059 controls with atrial fibrillation, and 22\u2009266 controls without atrial fibrillation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Primary outcome was incidence of stroke or TIA. Secondary outcome was all cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Adjusted incidence rate ratios for stroke or TIA in patients with resolved atrial fibrillation were 0.76 (95% confidence interval 0.67 to 0.85, P&lt;0.001) versus controls with atrial fibrillation and 1.63 (1.46 to 1.83, P&lt;0.001) versus controls without atrial fibrillation. Adjusted incidence rate ratios for mortality in patients with resolved atrial fibrillation were 0.60 (0.56 to 0.65, P&lt;0.001) versus controls with atrial fibrillation and 1.13 (1.06 to 1.21, P&lt;0.001) versus controls without atrial fibrillation. When patients with resolved atrial fibrillation and documented recurrent atrial fibrillation were excluded the adjusted incidence rate ratio for stroke or TIA was 1.45 (1.26 to 1.67, P&lt;0.001) versus controls without atrial fibrillation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with resolved atrial fibrillation remain at higher risk of stroke or TIA than patients without atrial fibrillation. The risk is increased even in those in whom recurrent atrial fibrillation is not documented. Guidelines should be updated to advocate continued use of anticoagulants in patients with resolved atrial fibrillation.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmj.k1717","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:40:22Z","timestamp":1676551222000},"page":"k1717","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies"],"prefix":"10.1136","author":[{"given":"Nicola J","family":"Adderley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"2023031422564814000_361.may09_14.k1717.1","unstructured":"The National Collaborating Centre for Chronic Conditions . Atrial Fibrillation. National clinical guideline for management in primary and secondary care. Royal College of Physicians, 2006."},{"key":"2023031422564814000_361.may09_14.k1717.2","unstructured":"National Clinical Guideline Centre . Atrial fibrillation: the management of atrial fibrillation. Clinical guideline: Methods, evidence and recommendations. London. National Institute for Health and Care Excellence, 2014."},{"key":"2023031422564814000_361.may09_14.k1717.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"2023031422564814000_361.may09_14.k1717.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7336.S71"},{"key":"2023031422564814000_361.may09_14.k1717.5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001927.pub2"},{"key":"2023031422564814000_361.may09_14.k1717.6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006186.pub2"},{"key":"2023031422564814000_361.may09_14.k1717.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318214876d"},{"key":"2023031422564814000_361.may09_14.k1717.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.019927"},{"key":"2023031422564814000_361.may09_14.k1717.9","unstructured":"National Institute for Health and Clinical Excellence . Atrial fibrillation. The management of atrial fibrillation. NICE Clinical Guideline 36. National Institute for Health and Clinical Excellence, 2006."},{"key":"2023031422564814000_361.may09_14.k1717.10","unstructured":"National Institute for Health and Care Excellence . Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 180. National Institute for Health and Care Excellence, 2014."},{"key":"2023031422564814000_361.may09_14.k1717.11","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.01.18"},{"key":"2023031422564814000_361.may09_14.k1717.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.968032"},{"key":"2023031422564814000_361.may09_14.k1717.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.04.060"},{"key":"2023031422564814000_361.may09_14.k1717.14","unstructured":"General Practitioners Committee, NHS Employers and NHS England. 2016\/17 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF) Guidance for GMS contract 2016\/17 London: NHS Employers 2016."},{"key":"2023031422564814000_361.may09_14.k1717.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"2023031422564814000_361.may09_14.k1717.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2023031422564814000_361.may09_14.k1717.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.08.001"},{"key":"2023031422564814000_361.may09_14.k1717.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"2023031422564814000_361.may09_14.k1717.19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1688"},{"key":"2023031422564814000_361.may09_14.k1717.20","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-303472"},{"key":"2023031422564814000_361.may09_14.k1717.21","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X691685"},{"key":"2023031422564814000_361.may09_14.k1717.22","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310927"},{"key":"2023031422564814000_361.may09_14.k1717.23","unstructured":"NHS England . New GMS Contract QOF Implementation. Dataset and Business Rules. Atrial Fibrillation Indicator Set. Health and Social Care Information Centre, 2016."},{"key":"2023031422564814000_361.may09_14.k1717.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004958"},{"key":"2023031422564814000_361.may09_14.k1717.25","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.069492"},{"key":"2023031422564814000_361.may09_14.k1717.26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005155"},{"key":"2023031422564814000_361.may09_14.k1717.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu307"},{"key":"2023031422564814000_361.may09_14.k1717.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004267"},{"key":"2023031422564814000_361.may09_14.k1717.29","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002329"},{"key":"2023031422564814000_361.may09_14.k1717.30","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv401"},{"key":"2023031422564814000_361.may09_14.k1717.31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw087"},{"key":"2023031422564814000_361.may09_14.k1717.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2015.02.020"},{"key":"2023031422564814000_361.may09_14.k1717.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.07.002"},{"key":"2023031422564814000_361.may09_14.k1717.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.025"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.k1717","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.k1717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:57:04Z","timestamp":1678859824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.k1717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":34,"alternative-id":["10.1136\/bmj.k1717"],"URL":"https:\/\/doi.org\/10.1136\/bmj.k1717","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]}}}